SITC Updates

NEW! SITC 40th Anniversary: I-O Progress and Potential

By JITC Publications posted 10 days ago
In celebration of the 40 th Anniversary of the Society for Immunotherapy of Cancer (SITC), the Journal for ImmunoTherapy of Cancer ( JITC ) presents this special series of commentaries from luminaries in the field of immuno-oncology. Numerous SITC Fellows of the Academy of Immuno-Oncology and Richard V. Smalley Memorial Award recipients put pen to paper to provide their insights into current achievements in various areas of the field while also sharing their personal, forward-looking vision of where the field is moving in the upcoming decades. As SITC looks forward with anticipation of exciting new developments, JITC aims to deepen the science of cancer ...

SITC Thanks Members for Participating in Their 2025 Capitol Hill Visits!

By SITC Advocacy posted 10 days ago
SITC’s 2025 Capitol Hill Visits have officially concluded after engaging with over 25 congressional offices! During these meetings, SITC members passionately advocated for the inclusion of SITC’s FY26 appropriations language, emphasizing the need for utilizing novel technologies to advance the field’s understanding of the tumor microenvironment and AI’s potential for developing next generation immunotherapies. We extend our sincere thanks to all the SITC members who volunteered their time and expertise to participate. We couldn't do this without you! See SITC’s full FY26 language HERE . #Policy #SITContheHill
 
Cancer Research Policy User-Generated   SITContheHill

2025 AACR Annual Meeting (April 25–30, 2025)

By Thomas Martin posted 10 days ago
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 AACR Annual Meeting. 2025 Scientific Highlights Addition of perioperative pembrolizumab to the standard of care significantly improves event free survival in patients with head and neck squamous cell carcinoma CT001. Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study Ravindra Uppaluri (Brigham and Women's Hospital and Harvard Medical School/Dana-Farber Cancer ...

SITC Statement on Major Staff Reductions at the Department of Health and Human Services

By SITC Advocacy posted 11 days ago
Dear SITC Members, The Society for Immunotherapy of Cancer (SITC) strongly opposes the recent actions asking for a significant reduction in staff at the Department of Health and Human Services (HHS). As an organization dedicated to advancing the science and application of cancer immunotherapy to make the word "cure" a reality for patients, SITC is deeply concerned that these cuts are already resulting in profound and detrimental impact on the United States' research and development ecosystem, delaying the progress of life-saving therapies to those who need them most. One of the most immediate and damaging consequences of these reductions is the loss ...

SITC’s 2025 Capitol Hill Visits!

By SITC Advocacy posted 12 days ago
SITC is pleased to announce the kickoff of SITC’s 2025 in person Capitol Hill Visits! Over the last few months SITC members have been meeting virtually with congressional offices all across the country to advocate for inclusion of SITC’s FY26 appropriations language aimed at utilizing novel technologies to advance the field’s understanding of the tumor microenvironment and AI’s potential for developing next generation immunotherapies. These meetings have served as important opportunities for SITC to share the impact cancer immunotherapy has had on the field, and the critical need for further support from FDA and NCI to continue the momentum in trying to make ...
 
Source Policy User-Generated   SITContheHill

Oncology News Burst from the FDA: FDA Approves Penpulimab-kcqx for Non-Keratinizing Nasopharyngeal Carcinoma

By SITC Communications posted 16 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Call for Comment: SITC Renal Cell Carcinoma CPG v3.0 Until May 8

By SITC Scientific Publications News posted 19 days ago
Manuscript Title: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0 Draft Manuscript Summary The Society for Immunotherapy of Cancer (SITC) Renal Cell Carcinoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma,” an update to the society’s 2019 CPG for this disease setting. The new RCC manuscript is part of the broader SITC Cancer Immunotherapy Guidelines ...

Call for Comment: SITC Renal Cell Carcinoma CPG v3.0 Until May 8

By SITC Scientific Publications News posted 19 days ago
Manuscript Title: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0 Draft Manuscript Summary The Society for Immunotherapy of Cancer (SITC) Renal Cell Carcinoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma,” an update to the society’s 2019 CPG for this disease setting. The new RCC manuscript is part of the broader SITC Cancer Immunotherapy Guidelines ...

JITC Digest April 2025

By JITC Publications posted 25 days ago
INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks | JITC at AACR 2025 40 th Anniversary Series | Popular Archive Articles Letter from the Editor Hello JITC Readers, I just returned from London with other Editors-in-Chief for the 76 journals (like ours) published by the BMJ Group. We focused on many issues that confront our knowledge workers in the modern era, including the use of multimedia, ethics, how to improve the quality of content and… the state of our world. I was asked by many there to address what was happening politically in the U.S. Indeed, ...

JITC Digest April 2025

By JITC Publications posted 25 days ago
INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks | JITC at AACR 2025 40 th Anniversary Series | Popular Archive Articles Letter from the Editor Hello JITC Readers, I just returned from London with other Editors-in-Chief for the 76 journals (like ours) published by the BMJ Group. We focused on many issues that confront our knowledge workers in the modern era, including the use of multimedia, ethics, how to improve the quality of content and… the state of our world. I was asked by many there to address what was happening politically in the U.S. Indeed, ...

Oncology News Burst from the FDA: FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma

By SITC Communications posted 27 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Oncology News Burst from the FDA: FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

By SITC Communications posted 04-09-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

SITC Hosts Advanced Biomarker Development and Clinical Translation: Computational Science in Immuno-oncology Webinar

By SITC Advocacy posted 04-09-2025
This webinar on April 2 explored what b iomarker discovery for cancer immunotherapy entails using high-dimensional multi- omic assays that can be difficult to interpret, particularly in the setting of challenging clinical trial designs such as small cohort size or unbalanced response rates. This webinar therefore addressed advances in computational science and biostatistics that allow for rigorous interpretation of complex exploratory biomarker data, when most studies are typically only powered for clinical endpoints. View the webinar for FREE on-demand HERE.

NEW! The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)

By JITC Publications posted 04-06-2025
The rapid clinical and scientific progress of immuno-oncology (IO) since the approval of the first immune checkpoint inhibitors has changed the spectrum of patient care forever. Recognizing the milestones of the past and considering the obstacles ahead for the field, the Society for Immunotherapy of Cancer (SITC) capitalized on this critical inflection point to convene a diverse group of experts in cancer immunotherapy, from academia, the pharmaceutical and biotechnology industries, patient advocacy, and the regulatory community, to provide a roadmap to the next wave of novel immuno-therapies for cancer patients. Within this JITC special series, leading ...

Oncology News Burst from the FDA: FDA Approves Durvalumab for Muscle Invasive Bladder Cancer

By SITC Communications posted 04-01-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

SITC Publishes Manuscript on Essential Biomarkers for Immunotherapy Clinical Protocols

By SITC Scientific Publications News posted 04-01-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a comprehensive manuscript, “Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols” in the Journal for ImmunoTherapy of Cancer (JITC) . This work provides an in-depth examination of evidence-based biomarkers that measure the potential for therapeutic response and/or toxicity that are critical to guide optimal patient care and contextualize the results of immunotherapy clinical trials. Responding to the lack of guidance on biomarker testing in early phase immunotherapy clinical trials, SITC proposes ...

SITC Thanks FDA Leaders for Their Service

By Keegan Mager posted 03-31-2025
Dear SITC Members, The Society for Immunotherapy of Cancer (SITC) would like to thank Peter Marks, MD, PhD, Marc Theoret, MD, and Paul Kluetz, MD, of the U.S. Food and Drug Administration (FDA) for their significant contributions across the field of oncology and their positive impact on public health. The development of cancer immunotherapy as we know it today - serving as first-line treatment for numerous cancer types - represents one such advance in oncology that would not have been possible without the tireless work ethic, collaboration, and determination of these individuals to improve cancer patient outcomes and save lives. Peter Marks, ...

Immune Monitor - March 2025

By SITC Communications posted 03-28-2025
A Message from the President For 40 years, the Society for Immunotherapy of Cancer (SITC) has been dedicated to improving patient outcomes by advancing the science, development, and application of cancer immunotherapy. We achieve this through providing essential education, fostering global connections among professionals across all work settings, and serving as the leading voice in the cancer immunotherapy field. Recent federal actions are clearly having significant impacts on the fields of science and medicine. SITC is working closely with our trusted government consultant in Washington, DC to stay informed on the rapidly shifting landscape. ...

Announcing the publication of “Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols”

By SITC Advocacy posted 03-26-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a comprehensive manuscript, “Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols” in the Journal for ImmunoTherapy of Cancer (JITC). This work provides an in-depth examination of evidence-based biomarkers that measure the potential for therapeutic response and/or toxicity are critical to guide optimal patient care and contextualize the results of immunotherapy clinical trials. Responding to the lack of guidance on biomarker testing in early phase immunotherapy clinical trials, The Society for ...

Lymphoma CPG Update V1.4 Now Available

By SITC Scientific Publications News posted 03-24-2025
An update to " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma ” is now available. In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital ...